SM-88 | Tyrosine metabolism inhibitor

SM-88 supplier | CAS 30625-05-9 | Focus Biomolecules

Available Options

SizePriceQuantity 
10mg$40.00
50mg$125.00
Request Quote / Bulk / Custom Size
Product Inquiry
This product is also available in the following library:
Cancer Cell Metabolism Library

SM-88 (30625-05-9) is a “dysfunctional” tyrosine mimetic. It is taken up by cancer cells and disrupts tyrosine-mediated metabolic pathways including synthesis of the important protein mucin-1 leading to oxidative stress.1 In clinical trials with melanin, phenytoin, and sirolimus (SMK therapy) for use in advanced metastatic cancer2, in combination with methoxsalen, phenytoin, and sirolimus (MPS therapy) for prostate cancer3, and as monotherapy for metastatic pancreatic cancer4.  It is also an inhibitor of tyrosine hydroxylase resulting in a reduction of catecholamines and their metabolites.5

References/Citations:

  1. Lemberg et al. (2022), Clinical development of metabolic inhibitors for oncology; J. Clin. Invest., 132 e148550
  2. Stega et al. (2020), A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer; Invest. New Drugs, 38 392
  3. Gartell et al. (2021), Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer; Invest. New Drugs, 39 499
  4. Noel et al. (2019), Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage J. Clin. Oncol., 37 200
  5. Brogden et al. (1981), alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use; Drugs, 21 81
30625-05-9, DL-alpha-methyltyrosine, dysfunctional tyrosine mimetic, Racemetyrosine, SM-88, SM-88 supplier, SM88, tyrosine mimetic
Alternate Name:
Racemetyrosine HCl; DL-alpha-methyltyrosine HCl

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

SM-88 (30625-05-9) is a “dysfunctional” tyrosine mimetic. It is taken up by cancer cells and disrupts tyrosine-mediated metabolic pathways including synthesis of the important protein mucin-1 leading to oxidative stress.1 In clinical trials with melanin, phenytoin, and sirolimus (SMK therapy) for use in advanced metastatic cancer2, in combination with methoxsalen, phenytoin, and sirolimus (MPS therapy) for prostate cancer3, and as monotherapy for metastatic pancreatic cancer4.  It is also an inhibitor of tyrosine hydroxylase resulting in a reduction of catecholamines and their metabolites.5

References/Citations:

  1. Lemberg et al. (2022), Clinical development of metabolic inhibitors for oncology; J. Clin. Invest., 132 e148550
  2. Stega et al. (2020), A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer; Invest. New Drugs, 38 392
  3. Gartell et al. (2021), Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer; Invest. New Drugs, 39 499
  4. Noel et al. (2019), Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage J. Clin. Oncol., 37 200
  5. Brogden et al. (1981), alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use; Drugs, 21 81